Executive Vice President of R&D and Chief Medical Officer — Dr. Kristen K. Buck, M.D.: The employment of Dr. Kristen K. Buck was terminated as part of a workforce reduction.

Costs Associated with Exit or Disposal Activities. On August 3, 2026, the board of directors (the “Board”) of Lisata Therapeutics, Inc. (the “Company”) approved a reduction in workforce by approximately 72%, effective immediately. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options. Affected employees will be offered separation benefits, including severa…

Termination of a Material Definitive Agreement On July 24, 2026, Lisata Therapeutics, Inc. (the “Company”) terminated the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva Labs Inc., a Delaware corporation (“Parent”) and Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the Company (as amended, the “Merger Agreement”), pursuant to Section 8.3(a) of the Merger Agreement (the “Termination”). Pu…

Other Events The Company’s Board of Directors plans to conduct an assessment of strategic options to enhance stockholder value, which will include, but are not limited to, a reverse merger, other business combination, sales of assets, dissolution or other strategic transactions. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements will be reached, or transactions will be successfully consu…

Entry into a Material Definitive Agreement On July 16, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment (the “Amendment”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (as it may be amended from time to…

Entry into a Material Definitive Agreement On June 8, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment and waiver (the “Amendment”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (as it may be amended fro…

Other Events As previously announced, on May 29, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment (the “Amendment”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (as it may be amended from time to time,…

Entry into a Material Definitive Agreement On May 29, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment (the “Amendment”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (the “Original Merger Agreement” and…

Entry into a Material Definitive Agreement On May 3, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment and waiver (the “Amendment and Waiver”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (the “Merger Ag…

Other Events As previously disclosed, on April 2, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), agreed to extend the date by which Purchaser is obligated to commence the tender offer for all of the outstanding shares of common stock of the Company pursuant to the previously announced Agreement and Plan of Merge…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On March 6, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “Company” or “Lisata”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kuva Labs Inc., a Delaware corporation (“Parent”), and Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Pur…

Regulation FD Disclosure. On March 6, 2026, the Company issued a press release announcing the execution of the Merger Agreement. A copy of the press release is attached as Exhibit 99.1 thereto and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the li…

Entry into a Material Definitive Agreement. Reference is made to the binding term sheet (the “Term Sheet”), dated as of January 20, 2026, by and between Lisata Therapeutics, Inc. (“Lisata”) and Kuva Labs Inc. (“Kuva”), pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by Kuva (the “Purchase Agreement”) whereby Kuva will commence a tender offer to purchase, on a fully-diluted basis,…

Other Events. On January 23, 2026, Lisata Therapeutics, Inc. (the “Company”) and Qilu Pharmaceutical Co., Ltd. (“Qilu”) entered into a Mutual Termination Agreement (the “Termination Agreement”) relating to the Exclusive License and Collaboration Agreement between the Company (formerly Cend Therapeutics, Inc.) and Qilu, relating to the research, development and commercialization of certepetide (formerly known as CEND-1), dated February 11, 2021, as amended on April 26, 2021, and further amende…

Entry into a Material Definitive Agreement. Term Sheet On January 20, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ Lisata ”), entered into a binding term sheet (the “ Term Sheet ”) with Kuva Labs Inc., a Delaware corporation (“ Kuva ”), pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by Kuva (the “ Purchase Agreement ”) whereby Kuva will commence…

Other Events. Press Release On January 21, 2026, the Company issued a press release regarding the execution of the Term Sheet. A copy of such press release has been furnished herewith as Exhibit 99.1 to this Report and is incorporated herein by reference. Additional Information and Where to Find It The tender offer described above has not yet commenced. This communication is not an offer to buy nor a solicitation of an offer to sell any securities of the Company. The solicitation and the offe…

Results of Operations and Financial Condition. The information in

Entry into a Material Definitive Agreement. Non-Exclusive License Agreement On October 8, 2025, Lisata Therapeutics, Inc. (the “Company”) entered into a worldwide Non-Exclusive License Agreement (the “Non-Exclusive License Agreement” or the “Agreement”) with Catalent, Inc. (“Catalent”), pursuant to which the Company granted to Catalent, on a non-exclusive basis, certain of its intellectual property to exploit use of the Company’s novel iRGD cyclic peptide, certepetide, as an antibody drug con…

Results of Operations and Financial Condition. The information in

Results of Operations and Financial Condition. Lisata Therapeutics, Inc. (the “Company”) previously reported in its 10-Q for the period ended March 31, 2025, that it had cash, cash equivalents and marketable securities of approximately $25.8 million, which, based on its existing and planned activities, would support its operations into the third quarter of 2026. The Company now believes that available funds will support current operations into the fourth quarter of 2026.

David J. Mazzo, Ph.D.: The filing details amendments to the employment agreement of Dr. David J. Mazzo, including changes in base salary and severance benefits.

Results of Operations and Financial Condition. The information in

Results of Operations and Financial Condition. The information in

Entry into a Material Definitive Agreement. Exclusive License and Collaboration Agreement On November 30, 2024, Lisata Therapeutics, Inc. (the “Company”) entered into an exclusive license and collaboration agreement (the “License and Collaboration Agreement” or the “Agreement”) with Kuva Labs, Inc. a wholly-owned subsidiary of Mi2 Holdings, LLC (“Kuva”), pursuant to which the Company granted a worldwide royalty bearing exclusive license (the “Exclusive License”) for the development and commer…

Results of Operations and Financial Condition. The information in